Aeon, the Winterthur-based healthtech combining full-body MRI scans with AI-driven disease detection, closed a seed extension Saturday that pushed its total seed capital past €12 million—roughly $14 million—according to EU-Startups. The round was co-led by Arāya Ventures alongside existing backers including Concentric, GoHub Ventures, and Kadmos Capital.
The Swiss startup also announced it had acquired Aware Health, a German blood diagnostics platform serving nearly 10,000 customers across Germany, Austria, and the Netherlands. Aeon says the deal compresses its longitudinal health data timeline by two years, a claim that reflects the company's broader bet: that pairing imaging, blood work, and machine learning can catch disease years before symptoms emerge.
It's an ambitious premise, and one that's drawing capital across Europe. Aeon's funding lands amid a broader wave of preventive health investment—Stockholm's Neko Health raised €612.7 million in a Series C, while competitors Tandem Health and Lucis have collectively raised over €100 million in recent rounds, EU-Startups reported. Whether the model proves durable at scale remains an open question, but investor appetite for early detection is undeniable.
The Product: 60 Minutes, 500 Conditions
Aeon's core offering is a 60-minute check-up anchored by roughly 50 minutes of non-contrast whole-body MRI. The scan sweeps brain, chest, abdomen, pelvis, spine, and soft tissue using multi-parametric techniques including diffusion-weighted imaging, according to the company. Patients also undergo blood analysis and can opt for genetic testing.
The company's AI layer automates much of the imaging interpretation, cross-referencing MRI findings against blood biomarkers and genetic markers to flag anomalies. Aeon says its predictive models assess risk across more than 500 conditions, feeding results into a longitudinal record that radiologists and physicians review before delivery to patients.
According to statements Aeon provided to Tech.eu and EU-Startups, the platform has logged zero false positives in clinical-grade follow-ups to date. Eleven percent of users have received a significant health finding before developing symptoms, the company said, and more than 90 percent of check-ups surface what Aeon describes as actionable findings. Those figures, while striking, have not been independently audited or published in peer-reviewed literature.
The company launched its service in 2024 and currently operates clinics in Zurich and Bern, serving patients primarily in Switzerland and Germany. The company says Germany has become its fastest-growing market.
Founder Credentials and Acquisition Strategy
Tim Seithe, Aeon's founder and CEO, brings an operational track record from his previous venture, Tillhub, a Berlin point-of-sale software firm he sold to Unzer—a payments company majority-owned by KKR—in April 13, 2022. Co-founder Samuel Frey, who serves as chief product officer, previously led product at Platomics.
The Aware Health acquisition adds more than draw locations and customer volume. It gives Aeon a recurring diagnostics infrastructure, something Seithe sees as central to building predictive models over time. "Imaging tells you where you are. Blood diagnostics tell you where you are heading. AI is what connects the two into prediction," he told EU-Startups.
Aware Health's platform offers access to over 90 biomarkers through 15-minute appointments at more than 45 locations. The service relies on an app interface and certified labs to deliver results, a lower-cost complement to Aeon's MRI-heavy approach.
This isn't Aeon's first tuck-in deal. The company acquired holsain, a firm specializing in MRI screening protocols and body composition analysis, in November, according to Dealroom. The moves suggest Seithe is building through both organic growth and strategic acquisitions, a pattern familiar in early-stage healthtech where assembling capabilities quickly can matter as much as developing them in-house.
Insurance Dynamics and Market Access
One persistent challenge for preventive imaging startups is reimbursement. Switzerland's basic health insurance does not cover full-body MRI for asymptomatic patients, a regulatory stance common across much of Europe. Aeon has secured partial coverage through Swiss insurer KPT, which offers up to 75 percent reimbursement under certain supplementary plans, according to the company's website. How widely that model can expand—and whether other insurers follow—will likely shape Aeon's addressable market.
Germany's regulatory landscape presents a different calculus, and the Aware Health acquisition positions Aeon to navigate it with an established network. Ferdinand Schmidt-Thomé, Aware Health's co-founder, said the combination with Aeon's imaging and AI "genuinely changes what preventive health looks like in Europe," according to EU-Startups.
Capital History and Board Composition
Aeon initially raised €8.2 million in a seed round on June 4, 2025, led by Concentric with backing from Calm/Storm Ventures, GoHub Ventures, Kadmos Capital, EWOR, and Swiss angel investor Daniel Gutenberg, Tech.eu reported. Alexander Stroud, a principal at Concentric, joined Aeon's board shortly after and has publicly endorsed the company's clinical approach. "Validated by insurers, Aeon is delivering the most medically robust preventive health product on the market," Stroud told Tech.eu at the time.
The seed extension brings several new names into the cap table, notably Arāya Ventures, whose founding partner Rupa Popat cited Aeon's longitudinal data play as a differentiator. "The combination of imaging, recurring blood diagnostics, and AI creates a longitudinal health picture that no other platform in Europe offers," Popat said in the EU-Startups report.
Aeon currently employs between 11 and 50 people, according to LinkedIn and Dealroom profiles. The company is formally registered as MRI Health Holding AG and operates its headquarters in Winterthur, a small city northeast of Zurich better known for insurance than healthtech.
Whether Aeon can translate capital and acquisitions into sustainable clinical validation—and eventually, broader insurance adoption—remains the next test. For now, it's riding a tailwind that shows little sign of abating.
